NCT02760498 · OUTCOME
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma · Source last updated 2025-05-28
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- score on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline, Up to Cycle 12 Day 1 (Week 89)
What was measured
EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
Analysis population: The FAS included all enrolled participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and "Number Analyzed" is the number evaluable at each time point. Only Groups 1, 2, 3, and 4 were planned for this outcome measure.
Groups in this outcome
Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W
Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).
Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W
Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).
Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W
Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).
Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W
Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 44 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 68 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 38 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 54 |
|---|
Reported measurements
Cycle 2 Day 1 (C2D1)
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 42 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 60 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 34 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 52 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 0.00 | 21.464 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 5.56 | 18.895 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 6.86 | 19.621 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 0.96 | 17.670 | Not reported | Not reported | Not reported |
|---|
C3D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 37 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 55 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 30 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 43 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 11.26 | 19.267 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 5.30 | 21.717 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 15.28 | 20.655 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 3.88 | 15.680 | Not reported | Not reported | Not reported |
|---|
C4D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 36 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 39 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 29 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 38 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 6.25 | 25.069 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 8.76 | 19.585 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 13.51 | 22.539 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 4.39 | 15.099 | Not reported | Not reported | Not reported |
|---|
C5D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 36 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 41 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 27 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 36 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 4.17 | 22.316 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 8.33 | 21.246 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 13.27 | 21.466 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 5.79 | 18.774 | Not reported | Not reported | Not reported |
|---|
C6D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 31 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 44 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 26 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 33 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 5.11 | 17.437 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 5.68 | 28.118 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 12.18 | 24.521 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 0.25 | 21.599 | Not reported | Not reported | Not reported |
|---|
C7D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 32 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 40 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 12 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 15 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 6.51 | 17.676 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 9.17 | 22.393 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 22.22 | 23.659 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 4.44 | 18.598 | Not reported | Not reported | Not reported |
|---|
C8D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 29 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 33 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 11 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 15 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 4.60 | 21.080 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 10.10 | 21.425 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 30.30 | 19.816 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 5.00 | 25.158 | Not reported | Not reported | Not reported |
|---|
C9D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 26 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 29 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 10 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 13 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 6.09 | 18.938 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 6.61 | 26.199 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 26.67 | 24.470 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 7.69 | 20.543 | Not reported | Not reported | Not reported |
|---|
C10D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 27 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 23 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 9 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 10 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 12.04 | 20.844 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 13.77 | 26.064 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 28.70 | 13.889 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 5.83 | 22.923 | Not reported | Not reported | Not reported |
|---|
C11D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 25 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 19 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 10 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 9 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 10.33 | 28.186 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 11.40 | 22.603 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 32.50 | 14.407 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 14.81 | 19.444 | Not reported | Not reported | Not reported |
|---|
C12D1
Analysis denominator · Participants
| Group | Source count |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 24 |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 17 |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 9 |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 9 |
|---|
Values in score on a scale · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W | 8.33 | 22.388 | Not reported | Not reported | Not reported |
|---|
| Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W | 12.75 | 24.494 | Not reported | Not reported | Not reported |
|---|
| Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W | 27.78 | 16.667 | Not reported | Not reported | Not reported |
|---|
| Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W | 2.78 | 26.021 | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 21.464
- value
- 0.00
- group Id
- OG001
- spread
- 18.895
- value
- 5.56
- group Id
- OG002
- spread
- 19.621
- value
- 6.86
- group Id
- OG003
- spread
- 17.670
- value
- 0.96
- denoms
- counts
- group Id
- OG000
- value
- 42
- group Id
- OG001
- value
- 60
- group Id
- OG002
- value
- 34
- group Id
- OG003
- value
- 52
- units
- Participants
- title
- Cycle 2 Day 1 (C2D1)
- categories
- measurements
- group Id
- OG000
- spread
- 19.267
- value
- 11.26
- group Id
- OG001
- spread
- 21.717
- value
- 5.30
- group Id
- OG002
- spread
- 20.655
- value
- 15.28
- group Id
- OG003
- spread
- 15.680
- value
- 3.88
- denoms
- counts
- group Id
- OG000
- value
- 37
- group Id
- OG001
- value
- 55
- group Id
- OG002
- value
- 30
- group Id
- OG003
- value
- 43
- units
- Participants
- title
- C3D1
- categories
- measurements
- group Id
- OG000
- spread
- 25.069
- value
- 6.25
- group Id
- OG001
- spread
- 19.585
- value
- 8.76
- group Id
- OG002
- spread
- 22.539
- value
- 13.51
- group Id
- OG003
- spread
- 15.099
- value
- 4.39
- denoms
- counts
- group Id
- OG000
- value
- 36
- group Id
- OG001
- value
- 39
- group Id
- OG002
- value
- 29
- group Id
- OG003
- value
- 38
- units
- Participants
- title
- C4D1
- categories
- measurements
- group Id
- OG000
- spread
- 22.316
- value
- 4.17
- group Id
- OG001
- spread
- 21.246
- value
- 8.33
- group Id
- OG002
- spread
- 21.466
- value
- 13.27
- group Id
- OG003
- spread
- 18.774
- value
- 5.79
- denoms
- counts
- group Id
- OG000
- value
- 36
- group Id
- OG001
- value
- 41
- group Id
- OG002
- value
- 27
- group Id
- OG003
- value
- 36
- units
- Participants
- title
- C5D1
- categories
- measurements
- group Id
- OG000
- spread
- 17.437
- value
- 5.11
- group Id
- OG001
- spread
- 28.118
- value
- 5.68
- group Id
- OG002
- spread
- 24.521
- value
- 12.18
- group Id
- OG003
- spread
- 21.599
- value
- 0.25
- denoms
- counts
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 44
- group Id
- OG002
- value
- 26
- group Id
- OG003
- value
- 33
- units
- Participants
- title
- C6D1
- categories
- measurements
- group Id
- OG000
- spread
- 17.676
- value
- 6.51
- group Id
- OG001
- spread
- 22.393
- value
- 9.17
- group Id
- OG002
- spread
- 23.659
- value
- 22.22
- group Id
- OG003
- spread
- 18.598
- value
- 4.44
- denoms
- counts
- group Id
- OG000
- value
- 32
- group Id
- OG001
- value
- 40
- group Id
- OG002
- value
- 12
- group Id
- OG003
- value
- 15
- units
- Participants
- title
- C7D1
- categories
- measurements
- group Id
- OG000
- spread
- 21.080
- value
- 4.60
- group Id
- OG001
- spread
- 21.425
- value
- 10.10
- group Id
- OG002
- spread
- 19.816
- value
- 30.30
- group Id
- OG003
- spread
- 25.158
- value
- 5.00
- denoms
- counts
- group Id
- OG000
- value
- 29
- group Id
- OG001
- value
- 33
- group Id
- OG002
- value
- 11
- group Id
- OG003
- value
- 15
- units
- Participants
- title
- C8D1
- categories
- measurements
- group Id
- OG000
- spread
- 18.938
- value
- 6.09
- group Id
- OG001
- spread
- 26.199
- value
- 6.61
- group Id
- OG002
- spread
- 24.470
- value
- 26.67
- group Id
- OG003
- spread
- 20.543
- value
- 7.69
- denoms
- counts
- group Id
- OG000
- value
- 26
- group Id
- OG001
- value
- 29
- group Id
- OG002
- value
- 10
- group Id
- OG003
- value
- 13
- units
- Participants
- title
- C9D1
- categories
- measurements
- group Id
- OG000
- spread
- 20.844
- value
- 12.04
- group Id
- OG001
- spread
- 26.064
- value
- 13.77
- group Id
- OG002
- spread
- 13.889
- value
- 28.70
- group Id
- OG003
- spread
- 22.923
- value
- 5.83
- denoms
- counts
- group Id
- OG000
- value
- 27
- group Id
- OG001
- value
- 23
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 10
- units
- Participants
- title
- C10D1
- categories
- measurements
- group Id
- OG000
- spread
- 28.186
- value
- 10.33
- group Id
- OG001
- spread
- 22.603
- value
- 11.40
- group Id
- OG002
- spread
- 14.407
- value
- 32.50
- group Id
- OG003
- spread
- 19.444
- value
- 14.81
- denoms
- counts
- group Id
- OG000
- value
- 25
- group Id
- OG001
- value
- 19
- group Id
- OG002
- value
- 10
- group Id
- OG003
- value
- 9
- units
- Participants
- title
- C11D1
- categories
- measurements
- group Id
- OG000
- spread
- 22.388
- value
- 8.33
- group Id
- OG001
- spread
- 24.494
- value
- 12.75
- group Id
- OG002
- spread
- 16.667
- value
- 27.78
- group Id
- OG003
- spread
- 26.021
- value
- 2.78
- denoms
- counts
- group Id
- OG000
- value
- 24
- group Id
- OG001
- value
- 17
- group Id
- OG002
- value
- 9
- group Id
- OG003
- value
- 9
- units
- Participants
- title
- C12D1
- denoms
- counts
- group Id
- OG000
- value
- 44
- group Id
- OG001
- value
- 68
- group Id
- OG002
- value
- 38
- group Id
- OG003
- value
- 54
- units
- Participants
- description
- EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).
- id
- OG000
- title
- Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W
- description
- Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).
- id
- OG001
- title
- Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W
- description
- Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).
- id
- OG002
- title
- Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W
- description
- Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).
- id
- OG003
- title
- Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W
- param Type
- MEAN
- population Description
- The FAS included all enrolled participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure and "Number Analyzed" is the number evaluable at each time point. Only Groups 1, 2, 3, and 4 were planned for this outcome measure.
- reporting Status
- POSTED
- time Frame
- Baseline, Up to Cycle 12 Day 1 (Week 89)
- title
- Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score
- type
- SECONDARY
- unit Of Measure
- score on a scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle